ADC Resistance Overcome: ORR Exceeds 41%! The Potential of HER2 TKI Treatment in HER2+ NSCLC
Introduction Zongertinib (BI1810631) is a selective HER2 (ERBB2) tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim, which covalently binds to the receptor tyrosine kinase domain (TKD) of HER2 exon 20 mutations. This selectivity allows it to block only the abnormal downstream signaling of HER2 without affecting the wild-type epidermal growth factor receptor (wtEGFR, i.e., normal … Read more
